Corcept Therapeutics Target Price

See Corcept Therapeutics's analyst price targets ($110) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$110.43

Average Target Price

$113.25

2.6% upside

8 analysts in the last 4 months

High: $165 | Low: $50

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-08-18	Truist FinancialSrikripa Devarakonda	$164	48.5% upside
2026-07-30	H.C. WainwrightSwayampakula Ramakanth	$165	49.4% upside
2026-07-29	Canaccord GenuityEdward Nash	$150	35.8% upside
2026-07-27	Wolfe Research	$50	54.7% downside
2026-06-02	H.C. WainwrightSwayampakula Ramakanth	$95	14% downside
2026-05-28	UBS	$135	22.2% upside
2026-05-13	UBS	$72	34.8% downside
2026-05-04	H.C. Wainwright	$75	32.1% downside
2026-05-01	Piper Sandler	$88	20.3% downside
2026-02-20	H.C. Wainwright	$67	39.3% downside
2026-01-23	Canaccord Genuity	$100	9.4% downside
2026-01-22	H.C. WainwrightSwayampakula Ramakanth	$105	4.9% downside
2026-01-02	H.C. WainwrightSwayampakula Ramakanth	$90	18.5% downside
2026-01-02	Canaccord GenuityEdward Nash	$99	10.4% downside
2025-12-31	Truist Financial	$50	54.7% downside
2025-12-31	Wolfe Research	$30	72.8% downside
2025-12-16	UBSAshwani Verma	$95	14% downside
2025-09-10	Canaccord Genuity	$140	26.8% upside
2025-05-06	Truist FinancialJoon Lee	$135	22.2% upside
2025-05-06	H.C. WainwrightSwayampakula Ramakanth	$145	31.3% upside
2024-10-18	H.C. WainwrightSwayampakula Ramakanth	$80	27.6% downside
2024-09-30	Truist FinancialJoon Lee	$76	31.2% downside
2024-08-15	Canaccord GenuityEdward Nash	$78	29.4% downside
2024-07-30	Piper SandlerDavid Amsellem	$38	65.6% downside
2024-07-30	H.C. WainwrightSwayampakula Ramakanth	$45	59.3% downside
2024-06-12	Canaccord GenuityEdward Nash	$38	65.6% downside
2024-06-10	Piper SandlerDavid Amsellem	$35	68.3% downside
2024-06-04	Truist FinancialJoon Lee	$65	41.1% downside
2024-05-02	H.C. WainwrightSwayampakula Ramakanth	$40	63.8% downside
2022-12-09	H.C. Wainwright	$30	72.8% downside
2022-08-04	H.C. Wainwright	$33	70.1% downside

Corcept Therapeutics (CORT) FAQ

As of the most recent data, CORT shows a target price of $110. Scroll down for historical charts and peer comparison views.

If Corcept Therapeutics moved to the average analyst target of $110, shares would be roughly 2.6% higher than $110.43. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of Corcept Therapeutics's earnings trajectory.

Besides this target price page, Stockcircle has Corcept Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $110) with ownership activity and broader fundamentals.

Corcept Therapeutics's target price is $110; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.